Literature DB >> 11056211

Inhibition of interleukin-6 signaling by galiellalactone.

M Weidler1, J Rether, T Anke, G Erkel.   

Abstract

A search for inhibitors of the IL-6-mediated signal transduction in HepG2 cells using secreted alkaline phosphatase (SEAP) as reporter gene resulted in the isolation of galiellalactone (1) from fermentations of the ascomycete strain A111-95. Galiellalactone inhibits the IL-6-induced SEAP expression with IC(50) values of 250-500 nM by blocking the binding of the activated Stat3 dimers to their DNA binding sites without inhibiting the tyrosine and serine phosphorylation of the Stat3 transcription factor. Due to its selective activity, galiellalactone may serve as a lead compound for the development of new therapeutic agents for diseases originating from the inappropriate expression of IL-6 and as molecular tool to dissect the JAK/STAT pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056211     DOI: 10.1016/s0014-5793(00)02115-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 2.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

3.  STAT3 integrates cytokine and neurotrophin signals to promote sympathetic axon regeneration.

Authors:  Michael J Pellegrino; Beth A Habecker
Journal:  Mol Cell Neurosci       Date:  2013-07-03       Impact factor: 4.314

4.  Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.

Authors:  Nicholas Don-Doncow; Zilma Escobar; Martin Johansson; Sven Kjellström; Victor Garcia; Eduardo Munoz; Olov Sterner; Anders Bjartell; Rebecka Hellsten
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

Review 5.  Targeting STAT3 signaling in kidney disease.

Authors:  Jesse Pace; Praharshasai Paladugu; Bhaskar Das; John C He; Sandeep K Mallipattu
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

6.  Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol.

Authors:  Annegret Serwe; Kristina Rudolph; Timm Anke; Gerhard Erkel
Journal:  Invest New Drugs       Date:  2011-02-22       Impact factor: 3.850

Review 7.  Role of interleukin-6 in cancer progression and therapeutic resistance.

Authors:  Neeraj Kumari; B S Dwarakanath; Asmita Das; Anant Narayan Bhatt
Journal:  Tumour Biol       Date:  2016-06-03

Review 8.  Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Authors:  Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung
Journal:  Ann N Y Acad Sci       Date:  2009-08       Impact factor: 5.691

9.  The fungal secondary metabolite trichodimerol inhibits TGF-β dependent cellular effects and tube formation of MDA-MB-231 cells.

Authors:  Annegret Serwe; Timm Anke; Gerhard Erkel
Journal:  Invest New Drugs       Date:  2008-11-14       Impact factor: 3.850

10.  Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.

Authors:  Rebecka Hellsten; Martin Johansson; Anna Dahlman; Olov Sterner; Anders Bjartell
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.